Delcath Systems Inc (OQ:DCTH)

Mar 26, 2024 07:30 am ET
Feb 22, 2024 04:00 pm ET
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website. Potential patients, caregivers, and healthcare providers may use the Locator to identify healthcare settings, offering treatment with the HEPZATO KIT.
Feb 16, 2024 04:00 pm ET
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024.  
Jan 31, 2024 07:00 am ET
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Centers for Medicare & Medicaid Services ("CMS") has established a permanent and product-specific J-code (J9248) for HEPZATO. The J-code will become effective on April 1, 2024.
Jan 23, 2024 07:00 am ET
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Gerard Michel, CEO, will participate in a fireside chat moderated by Bill Maughan Ph.D., Senior Analyst at Canaccord Genuity, at the Lytham Partners 2024 Investor Select Conference. Management will also host virtual one-on-one meetings with investors.
Jan 16, 2024 07:00 am ET
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma (mUM).
Jan 12, 2024 04:00 pm ET
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in December 2023.  
Dec 07, 2023 08:00 am ET
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research
Retrospective Analysis of Changes in Patients with Metastatic Uveal Melanoma treated with Chemosat Hepatic Delivery System
Nov 15, 2023 04:00 pm ET
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals.
Nov 13, 2023 03:05 pm ET
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023.
Nov 06, 2023 03:30 pm ET
Delcath Systems to Host Third Quarter 2023 Results Call
NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.  
Oct 16, 2023 08:30 am ET
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers
Retrospective Comparison of Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma
Oct 10, 2023 08:30 am ET
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.
Oct 03, 2023 08:30 am ET
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023
NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the Roth MKM Healthcare Opportunities Conference in New York. Delcath CEO, Gerard Michel will present on October 12 at 11:45 AM ET.
Sep 27, 2023 04:05 pm ET
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Sept. 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, in the form of a total of 86,000 shares of the Company's common stock, outside of the Company's Omnibus 2020 Equity Incentive Plan as amended ("Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.  Delcath issued Ashleigh Lamson 20
Sep 11, 2023 08:00 am ET
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
Independent Investigator Study Compared Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma 
Jun 21, 2023 04:10 pm ET
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 21, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment for two individuals, the Chief Medical Officer, Vojislav Vukovic, and the Principal Accounting Officer and Principal Financial Officer, Sandra Pennell. 
Jun 20, 2023 08:30 am ET
Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer
NEW YORK, June 20, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.  Vojislav "Vojo" Vukovic as its new Chief Medical Officer (CMO).
Jun 07, 2023 04:10 pm ET
Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance
NEW YORK, June 7, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Ms. Pennell will also serve as an Executive Officer of the Company and its Principal Accounting Officer and Principal Financial Officer.
May 12, 2023 08:00 am ET
Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results
NEW YORK, May 12, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023.
May 09, 2023 09:00 am ET
Delcath Systems to Participate in the Lytham Partners Spring 2023 Investor Conference
NEW YORK, May 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.
May 03, 2023 08:30 am ET
Delcath Systems to Host First Quarter 2023 Results
NEW YORK, May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 12, 2023, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023.  
Apr 03, 2023 04:30 pm ET
Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility
Amendment with Avenue Venture Opportunities Fund, L.P. provides for an interest-only period from March 31, 2023 to September 30, 2023 and defers $4.3 million in principal payments
Mar 29, 2023 09:41 pm ET
Delcath Systems Announces Closing of Private Placement of up to $85 Million
Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors
Mar 27, 2023 08:20 am ET
Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
Mar 27, 2023 08:15 am ET
Delcath Systems Announces up to $85 Million Financing
Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors
Mar 27, 2023 08:10 am ET
Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023
NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new drug application resubmission for HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM). The FDA also communicated to Delcath that they consider the submission a com
Feb 16, 2023 07:30 am ET
Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch
NEW YORK, Feb. 16, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath's new Chairman. Mr. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units. In addition, Mr. Sylvester served as BTG plc's Chief Commercia
Jan 30, 2023 07:30 am ET
Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16.
Jan 17, 2023 07:00 am ET
Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology
Updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months
Dec 16, 2022 03:15 pm ET
Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)
NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to employment for one individual.
Dec 13, 2022 07:30 am ET
Delcath Systems Closes Private Placement of $6.2 Million
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement with certain accredited investors (the "Private Placement").
Dec 08, 2022 07:30 am ET
Delcath Systems Announces Private Placement of $6.2 Million
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement transaction (the "Private Placement").
Dec 05, 2022 08:00 am ET
Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis
Results show that percutaneous hepatic perfusion with CHEMOSAT® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in patients with inoperable, treatment-refractory liver metastases.
Nov 09, 2022 03:15 pm ET
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 9, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to employment to two individuals. The employees received a total of 40,000 shares of the Company's common stock, outside of the Company's Amended and Restated 2020 Stock Incentive Plan ("Plan"). The options were issued upon the employee's grant date ("Grant Date"), and all stock options included within the equity inducement award have an exercise price equal to the closing price of
Nov 08, 2022 07:00 am ET
Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update
NEW YORK, Nov. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2022.
Oct 24, 2022 04:05 pm ET
Delcath Systems to Host Third Quarter 2022 Results
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2022.  
Sep 01, 2022 04:15 pm ET
Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022
NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C. Wainwright 24th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 12 at 8:30 AM ET.
Aug 08, 2022 07:45 am ET
Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update
NEW YORK, Aug. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2022.
Aug 05, 2022 08:30 am ET
Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology
Retrospective study in metastatic uveal melanoma patients with liver dominant disease shows an objective response rate of 59.4% and a disease control rate of 89.1%. 
Jul 27, 2022 04:30 pm ET
Delcath Systems to Host Second Quarter 2022 Results
NEW YORK, July 27, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 8, 2022, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2022.  
Jul 20, 2022 04:10 pm ET
Delcath Systems Closes Private Placement of $5.0 Million
NEW YORK, July 20, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement for the issuance and sale of 690,954 shares of common stock (the "Common Stock") and 566,751 pre-funded warrants to purchase Common Stock (the "Pre-Funded Warrants") to certain investors. Each share of Common Stock was sold at a price per share of $3.98 and the Pre-Funded Warrants were sold at a price of $3.97 per Pre-Funded Warrant. Th
Jul 18, 2022 08:30 am ET
Delcath Systems Announces Private Placement of $5.0 Million
NEW YORK, July 18, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement transaction (the "Private Placement").
Jun 06, 2022 04:15 pm ET
Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced further details regarding presentations relating to its proprietary percutaneous...
May 10, 2022 07:30 am ET
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022....
May 09, 2022 08:30 am ET
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upcoming American Society of Clinical...
Apr 28, 2022 09:00 am ET
Delcath Systems to Host First Quarter 2022 Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 10, 2022, at 8:30 AM Eastern Time to discuss...
Apr 08, 2022 09:00 am ET
Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate in the Canaccord Genuity Horizons in Oncology Conference: Date: April 14, 2022...
Mar 29, 2022 09:00 am ET
Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference,...
Mar 25, 2022 07:30 am ET
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full-year ended...
Mar 15, 2022 04:30 pm ET
Delcath Systems to Host Fourth Quarter and Full Year 2021 Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss...
Mar 10, 2022 09:00 am ET
Delcath Systems to Present at the 34th Annual Roth Conference
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will present at the 34th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT. A webcast of...
Mar 02, 2022 04:01 pm ET
Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that on February 28 its CHEMOSAT Hepatic Delivery System received Medical...
Feb 22, 2022 09:00 am ET
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that effective March 1, 2022, it will resume direct responsibility for sales,...
Feb 10, 2022 04:30 pm ET
Delcath Systems to Present at Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:...
Feb 07, 2022 04:01 pm ET
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that the Company has appointed Anthony Dias as its new Vice President of Finance....
Feb 03, 2022 04:30 pm ET
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a single-institution retrospective study, conducted by University Hospital...
Jan 25, 2022 04:01 pm ET
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that David Hoffman has been appointed as General Counsel and Corporate Secretary. Mr....
Jan 07, 2022 09:00 am ET
Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: H.C. Wainwright...
Dec 02, 2021 08:00 am ET
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive results from the phase 3 FOCUS study. The FOCUS study’s intent-to-treat (ITT)...
Nov 30, 2021 08:30 am ET
Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting...
Nov 09, 2021 07:30 am ET
Delcath Systems Announces Third Quarter 2021 Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September...
Nov 08, 2021 09:00 am ET
Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: Canaccord...
Nov 05, 2021 09:00 am ET
Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a comprehensive Investor Update event on Thursday, December 2nd, from...
Oct 25, 2021 04:01 pm ET
Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss...
Sep 02, 2021 09:00 am ET
Delcath Systems to Present at Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences: H.C. Wainwright 23rd Annual Global...
Aug 10, 2021 07:30 am ET
Delcath Systems Announces Second Quarter 2021 Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30,...
Aug 09, 2021 07:30 am ET
Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund,...
Aug 05, 2021 09:00 am ET
Delcath Systems to Present at Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in two upcoming conferences: BTIG Virtual Biotechnology...
Jul 28, 2021 09:00 am ET
Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to...
Jul 08, 2021 11:20 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.
Jul 07, 2021 09:00 am ET
Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The...
Jun 23, 2021 09:35 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.
Jun 08, 2021 09:00 am ET
Delcath Systems Set to Join Russell Microcap® Index
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual...
Jun 07, 2021 07:30 am ET
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an oral presentation of positive preliminary efficacy results from its FOCUS Phase III...
Jun 03, 2021 09:00 am ET
Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at: LD Micro Virtual Investor ConferenceDate:...
May 26, 2021 09:00 am ET
Delcath Systems to Present at Jefferies Virtual Healthcare Conference
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at: Jefferies Virtual Healthcare Conference on June...
May 11, 2021 08:00 am ET
Delcath Systems, Inc. Announces First Quarter 2021 Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2021....
Apr 30, 2021 04:01 pm ET
Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on May 11, 2021 at 8:30 AM Eastern Time to discuss...
Apr 30, 2021 09:00 am ET
Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual...
Apr 21, 2021 08:38 am ET
Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE),...
Mar 31, 2021 02:55 pm ET
Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today provided additional information regarding the power calculation for the Phase 3 FOCUS trial of...
Mar 31, 2021 07:45 am ET
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter ended December 31,...
Mar 31, 2021 07:30 am ET
Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive top-line preliminary results from the company's Phase 3 FOCUS trial of...
Mar 24, 2021 04:01 pm ET
Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to...
Mar 08, 2021 09:00 am ET
Delcath Systems to Participate at Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:...
Feb 11, 2021 09:00 am ET
Delcath Systems to Participate at Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:...
Jan 11, 2021 10:56 am ET
Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference
Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual...
Dec 11, 2020 10:30 am ET
Delcath Systems Announces Completion of Underwritten Public Offering
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of its...
Dec 09, 2020 08:00 am ET
Delcath Systems Announces Pricing of Public Offering of Common Stock
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of an underwritten public offering of 1,460,027 shares of its common...
Dec 08, 2020 04:01 pm ET
Delcath Systems Announces Proposed Public Offering of Common Stock
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that it intends to offer and sell, subject to market conditions, shares of its...
Dec 07, 2020 07:30 am ET
Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations. In his...
Nov 11, 2020 08:00 am ET
Delcath Systems, Inc. Announces Third Quarter 2020 Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30,...
Nov 02, 2020 04:01 pm ET
Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced management will participate in the Oppenheimer Fall MedTech Summit on Thursday, November...
Nov 02, 2020 09:00 am ET
Delcath Schedules Conference Call to Report 2020 Third Quarter Financial Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that it will host a conference call on November 11, 2020 at 8:30 AM Eastern Time to...
Oct 29, 2020 07:30 am ET
Delcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular Melanoma
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that the Company will be hosting a Key Opinion Leader (KOL) call with Dr. Mark Burgmans,...
Oct 01, 2020 04:07 pm ET
Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer
Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effective October 1, 2020. Mr. Michel will also serve as a member of the Delcath Systems Board of Directors. In his...
Sep 28, 2020 10:50 am ET
Encode Ideas, L.P. to Host Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System's Phase 3 FOCUS Study
Dover, Delaware--(Newsfile Corp. - September 28, 2020) - Encode Ideas, L.P. announces they will be hosting a conference call with Dr. Jonathan Zager, surgical oncologist at Moffitt Cancer Center and the principal investigator for the Phase 3 FOCUS study, on Wednesday, September 30 at 3:00 pm Eastern Time. The purpose of the call will be to discuss the current metastatic ocular melanoma (mOM) treatment landscape, with a focus on the potential role that melphalan/hepatic delivery system via percutaneous hepatic perfusion could have on the management of mOM patients.
Sep 10, 2020 09:00 am ET
Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences: H.C....
Aug 31, 2020 05:00 pm ET
LD Micro 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 25, 2020 04:01 pm ET
Delcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ET
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday, September...
Aug 13, 2020 04:01 pm ET
Delcath Systems, Inc. Announces Second Quarter 2020 Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings call...
Aug 06, 2020 04:01 pm ET
Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that it will host a conference call on August 13, 2020 at 4:30 PM Eastern Time to...
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 03, 2020 01:48 pm ET
Delcath to Present at Canaccord Genuity 40th Annual Growth Conference
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting virtually on...
May 26, 2020 08:30 am ET
Delcath Announces Leadership Transition
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that the Board of Directors appointed John Purpura as interim Chief Executive...
May 19, 2020 08:30 am ET
Encode Ideas, L.P. Announces the Initiation of Research Coverage on Delcath Systems, Inc.
Dover, Delaware--(Newsfile Corp. - May 19, 2020) - Encode Ideas, L.P. Initiates Research on Delcath Systems, Inc (NASDAQ: DCTH). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:
May 15, 2020 06:30 am ET
Delcath Announces First Quarter 2020 Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended March 31, 2020. Highlights Completed $22.0...
May 05, 2020 04:05 pm ET
Delcath Systems Closes $22.0 Million Public Offering of Common Stock
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced underwritten public offering of 2.2...
May 01, 2020 10:17 am ET
Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
Delcath Systems, Inc. (OTCQB:DCTH  NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a $22 million underwritten public offering of 2.2...
Feb 19, 2020 08:30 am ET
Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board member with experience in pharma, biotech,...
Jan 13, 2020 08:30 am ET
Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced it has completed patient enrollment in its FOCUS registration trial intended to...
Dec 19, 2019 08:30 am ET
Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company’s Board of Directors has authorized a 1-for-700 reverse stock split of the...
Dec 03, 2019 08:30 am ET
Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019
Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that Dr. Jennifer Simpson, Ph.D., Chief Executive Officer and Ms. Barbra Keck, Chief Financial...
Oct 22, 2019 07:27 am ET
Delcath Systems Announces Postponement of Reverse Stock Split
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subsequent...
Oct 18, 2019 08:00 am ET
Delcath Systems Announces Ratio for Reverse Stock Split
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’s common...
Oct 08, 2019 08:00 am ET
Delcath Systems to Present at the MicroCap Rodeo Investor Conference
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will present at the MicroCap Rodeo. The conference will be held October 15-16, 2019 in Austin, Texas. Management will be available during the day on October 16, 2019...
Sep 23, 2019 11:30 am ET
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will participate at the following upcoming investor conferences in New York: Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019,...
Aug 28, 2019 08:00 am ET
Delcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will present at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright, at 5:05pm on Tuesday, September 10, 2019. The conference...
Aug 20, 2019 08:00 am ET
Delcath Systems Closes $9.5 Million Private Placement
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) has closed on its previously announced private placement with gross proceeds of $9.5 million at a combined price of $1,000 per Unit. Each Unit consists of one...
Aug 15, 2019 06:02 pm ET
Delcath Systems Announces $9.5 Million Private Placement
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for gross proceeds of approximately $9.5 million at a combined price of $1,000 per Unit. Each Unit...
Jul 29, 2019 08:00 am ET
Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester
Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that John R. Sylvester, a pharmaceutical and medical device executive with a greater than 30-year...
Jul 22, 2019 08:00 am ET
Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging
Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a single-institution retrospective study conducted by University Hospital...
Jul 17, 2019 04:05 pm ET
Delcath Systems Closes $20 Million Private Placement
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCPK: DCTH) has closed on its previously announced private placement with gross proceeds of $20 million at a combined price of $1,000 per Unit. Each Unit consists of one...
Jul 11, 2019 01:40 pm ET
Delcath Systems Announces $20 Million Private Placement
Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us”) (OTCPK: DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a combined price of $1,000 per Unit. Each Unit...
Apr 16, 2019 08:15 am ET
Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective phase 2 study conducted by Leiden University Medical Center...
Feb 28, 2019 10:38 am ET
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®—a global...
Feb 11, 2019 08:00 am ET
Delcath Announces Health Authority Approval for CHEMOSAT in Brazil
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has received medical device approval for the CHEMOSAT® Hepatic Delivery...
Feb 08, 2019 08:00 am ET
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use of the...
Dec 26, 2018 08:00 am ET
Delcath Announces Commercial Licensing Agreement for CHEMOSAT®
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization...
Dec 18, 2018 08:00 am ET
Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Registration trial for...
Nov 13, 2018 04:52 pm ET
Delcath Announces Third Quarter Fiscal 2018 Financial Results
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended September 30, 2018. Highlights from the third quarter of...
Oct 18, 2018 08:00 am ET
Delcath Announces Enrollment of First Patient in ALIGN Trial
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that patient treatments have begun in the Company’s second global US registration trial...
Oct 15, 2018 08:00 am ET
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amended trial...
Oct 04, 2018 08:00 am ET
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a multicenter analysis of outcomes in patients with intrahepatic...
Sep 27, 2018 04:05 pm ET
Delcath Raises $8.1 Million from Shareholders in Rights Offering
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces the closing of the subscription period of its previously announced rights offering. The rights...
Sep 26, 2018 08:00 am ET
Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective study conducted by Leiden University Medical Center (LUMC) in...
Sep 24, 2018 08:00 am ET
Data on Delcath’s PHP Therapy presented at CIRSE 2018
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that data from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT®...
Sep 13, 2018 08:00 am ET
Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights will be...
Sep 04, 2018 08:00 am ET
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic...
Aug 28, 2018 08:33 am ET
Delcath Announces Extension of Rights Offering Period to September 26, 2018
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an additional...
Aug 27, 2018 09:00 am ET
Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT®...
Aug 23, 2018 11:14 am ET
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 clinical trial for...
Aug 22, 2018 09:41 am ET
Delcath Announces Pending Expiration to Rights Offering Subscription Period
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday August 27, 2018, of the subscription period for...
Aug 21, 2018 08:52 am ET
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its registration...
Aug 20, 2018 08:00 am ET
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that patient enrollment has begun under the amended protocol for its registration trial in...
Aug 17, 2018 08:00 am ET
Delcath Issues Letter to Stockholders
Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief...
Aug 15, 2018 08:00 am ET
Delcath Announces Second Quarter Fiscal 2018 Financial Results
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June 30, 2018. Highlights from the second...
Aug 06, 2018 08:00 am ET
Delcath Announces Commencement of Rights Offering Subscription Period
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday, August 7,...
Jul 31, 2018 08:00 am ET
Summary of Calendar for Upcoming Proposed Delcath Rights Offering
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds investors that the ownership date cutoff for the Company’s upcoming rights offering is August 1, 2018...
Jul 27, 2018 08:00 am ET
Delcath Amends Phase 3 Ocular Melanoma Trial Protocol
Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has filed an amendment with the U.S. Food Drug Administration to revise...
Jul 16, 2018 08:00 am ET
Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018
Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights offering for...
Jul 09, 2018 08:00 am ET
Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands
Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led by Dr. Mark...
May 29, 2018 08:30 am ET
Delcath Systems to Present at the 8th Annual LD Micro Invitational
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at...
May 22, 2018 08:15 am ET
Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event.  A Cure in Sight...
May 16, 2018 08:00 am ET
Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath’s...
May 14, 2018 08:00 am ET
Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the Annual...
May 10, 2018 08:00 am ET
Delcath Announces First Quarter 2018 Financial Results
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended March 31, 2018. Highlights from the first quarter of 2018...
May 07, 2018 08:00 am ET
Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal trial of Melphalan Hydrochloride for Injection for use...
May 04, 2018 09:29 am ET
Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will...
May 03, 2018 08:30 am ET
Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial
Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for...
May 01, 2018 08:00 am ET
Delcath Announces Ratio for Reverse Split Authorization
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock...
Apr 09, 2018 08:00 am ET
Delcath Announces Shareholder Approval of Consent Solicitation
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that shareholders have approved the provisions of the Company’s Consent Solicitation...
Apr 03, 2018 08:00 am ET
Delcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology  
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Dr. Brian Steadman, Interventional Oncologist at the Southampton University Hospital...
Mar 29, 2018 08:00 am ET
Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that a comparative summary of recently published research on the Company’s...
Mar 19, 2018 04:05 pm ET
Delcath to Present at Oppenheimer 28th Annual Healthcare Conference
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...
Mar 16, 2018 09:00 am ET
Delcath Announces 2017 Financial Results
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the twelve months ended December 31, 2017.
Mar 12, 2018 08:00 am ET
Delcath to Present at 30th Annual Roth Conference
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...
Mar 08, 2018 09:00 am ET
OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
NEW YORK, March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market presenting companies at the 30th Annual ROTH Conference, taking place March 11-14 at The Ritz Carlton in Dana Point, California. 
Mar 07, 2018 08:00 am ET
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has entered into a commercial supply agreement with Tillomed Laboratories,...
Feb 02, 2018 08:00 am ET
Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have performed the 500th PHP Therapy® treatment...
Feb 01, 2018 08:00 am ET
Delcath Announces Satisfaction of 2016 Convertible Note
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has satisfied all of its obligations under the privately...
Jan 10, 2018 08:00 am ET
Delcath Announces Special Protocol Agreement Modification With FDA
NEW YORK, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has concluded a modification agreement with the U.S. Food...
Jan 09, 2018 08:30 am ET
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi-center retrospective analysis of Delcath’s PHP® Therapy...
Dec 29, 2017 08:35 am ET
Delcath Announces Exit from Convertible Note
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces on December 28, 2017, it entered into exchange agreements (collectively, “Exchange...
Dec 19, 2017 08:00 am ET
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial  
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase...
Dec 05, 2017 08:00 am ET
Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi-center retrospective analysis of Delcath’s PHP® Therapy...
Aug 08, 2017 09:30 am ET
Delcath Announces Second Quarter 2017 Financial Results
NEW YORK, Aug. 8, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2017.
Jun 05, 2017 05:15 pm ET
Delcath Systems, Inc. Announces Adjournment of Annual Meeting Meeting Scheduled to Reconvene on June 16
NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today that its 2017 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. The Annual Meeting has been adjourned until Friday, June 16, 2017 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 5, 2017, including a proposal to approve an amendment to its amended and resta...
May 09, 2017 08:00 am ET
Delcath Announces First Quarter 2017 Financial Results
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2017....
Apr 18, 2017 08:00 am ET
Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments
NEW YORK, April 18, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, commended Spire Southampton Hospital on the performance of over 100 percutaneous hepatic perfusion (PHP®) procedures with CHEMOSAT®. PHP with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver. The product is commercially available in Europe under the trade name CHEMOSAT, and is being evaluated as an investigational therapy in the U.S. Delcath is currently enrolling...
Mar 27, 2017 08:00 am ET
Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma
NEW YORK, March 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of Delcath’s pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). The SPA agreement indicates that the pivotal trial design adequately addresses obje...
Jan 23, 2017 08:00 am ET
Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017
NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will be a featured presenter at the NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Tuesday, January 31, 2017 at 10:30 am Eastern Standard Time.
Jan 18, 2017 08:00 am ET
New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that new data from a retrospective study of Melphalan/HDS, entitled "Percutaneous Hepatic Perfusion For Unresectable Metastatic Ocular Melanoma To The Liver: A Multi-Institutional Report Of Outcomes," has been accepted for oral presentation at the Regional Cancer Therapies 12th International Symposium, taking place February 18 - 20, 2017 at the Snowbird Ski and Summer Resort in Snowbird, UT.
Jan 12, 2017 08:30 am ET
Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort
NEW YORK, Jan. 12, 2017 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that patient treatment and data collection for the intrahepatic cholangiocarcinoma (ICC) cohort of its European Phase 2 HCC/ICC study is ongoing, and that the Company will announce interim results for the cohort once the data are fully mature. Additionally, the Company believes that the original goal to obtain an efficacy signal for the Phase 2 ICC cohort has been satisfied by the result of multicenter pat
Nov 11, 2016 07:30 am ET
Delcath Announces Third Quarter Financial Results
NEW YORK, Nov. 11, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and nine months ended September 30, 2016.
Oct 18, 2016 09:30 am ET
Delcath Issues Letter to Stockholders
NEW YORK, Oct. 18, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also been posted to the company's website, follows below.
Oct 17, 2016 09:30 am ET
Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy
NEW YORK, Oct. 17, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that a review of research conducted with the Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) has been accepted for publication by the prestigious medical journal, Advances in Therapy. The retrospective study, "Chemosaturation Percutaneous Hepatic Perfusion: A Systemic Review," was conducted by a team led by Dr. Arndt Vogel of the University of Hanover in Germany, and resulted from a CHEMOSAT Experts F
Oct 12, 2016 10:08 am ET
Delcath Announces First European Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases
NEW YORK, Oct. 12, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that five clinical sites in Europe have been activated and are open for patient enrollment in the Company's FOCUS Phase 3 clinical trial for patients with hepatic dominant ocular melanoma (the FOCUS Trial). The sites are the first centers in Europe to begin enrolling patients in the FOCUS Trial. One center, Charité University Hospital in Berlin, Germany, has treated its first patient. Delcath now has 13 ce
Oct 11, 2016 09:57 am ET
Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases
NEW YORK, Oct. 11, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that five new clinical trial sites in the U.S. have been activated in the Company's global FOCUS Phase 3 clinical trial for patients with hepatic dominant ocular melanoma (the FOCUS Trial). These accredited centers join several other prestigious centers as active participants in the FOCUS Trial. Currently, Delcath now has a total of 8 cancer centers in the U.S. open for patient enrollment in the FOCUS Tria
Oct 05, 2016 05:36 pm ET
Delcath To Present At The Dawson James Securities Growth Stock Conference
NEW YORK, Oct. 5, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the Dawson James Securities Growth Stock Conference taking place on October 20, 2016 in Jupiter, Florida. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present a corporate overview on October 20th at 2:15 p.m. Eastern time.
Sep 29, 2016 06:40 pm ET
Delcath Announces Proposed Public Offering of Common Stock and Warrants
NEW YORK, Sept. 29, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering.  The completion of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 
Sep 19, 2016 10:50 am ET
Delcath Sponsors Ocular Melanoma Foundation Patient Retreat
NEW YORK, Sept. 19, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on treatments for primary and metastatic liver cancers, announces that the company provided a grant to the Ocular Melanoma Foundation (OMF) in support of the organization's 6th Annual Eye Am Not Alone (EANA) patient education retreat, held in Miami, Florida at the Bascom Palmer Eye Institute on September 9-11, 2016. Delcath supported a lecture by Jonathan Zager, M.D., FACS, Professor of Surgery in the Cutaneous Oncology and Sarcoma Departments and a Senior Member at Moffi
Sep 12, 2016 05:05 pm ET
Delcath To Present At The 2016 Aegis Growth Conference
NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the 2016 Aegis Growth Conference taking place from September 20-22, 2016 in Las Vegas. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present a corporate overview on September 21st at 2:00 p.m. Pacific time.
Sep 12, 2016 09:42 am ET
Researchers at leiden univeristy medical center receive outstanding service award for Publication on Delcath's Melphalan/HDS
NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that a research team led by Dr. Mark C. Burgmans at Leiden University Medical Center (LUMC) in the Netherlands has received the prestigious Outstanding Service Award from Cardiovascular & Interventional Radiology (CVIR), a leading peer-reviewed medical journal. The LUMC team were recognized for their review of the Delcath Hepatic Delivery System (Melphalan/HDS), entitled, "Percutaneous Isolated Hepati
Aug 16, 2016 09:00 am ET
Delcath Announces Second Quarter Financial Results
NEW YORK, Aug. 16, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2016.
Jul 18, 2016 09:00 am ET
Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 2016
NEW YORK, July 18, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that abstracts from two studies conducted in Germany of use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with liver metastases, have been accepted for presentation as posters at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. The abstracts are:
Jul 07, 2016 09:00 am ET
Outcomes Study On Delcath's Melphalan/HDS In The Treatment Of Hepatic Metastases To Be Published In Cancer Control
NEW YORK, July 7, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that a review of clinical research treatment outcomes using Melphalan Hydrochloride for Injection with the Delcath Hepatic Delivery System (Melphalan/HDS) in patients with hepatic metastases has been accepted for publication in the prestigious journal, Cancer Control.  Results of the study, "Chemosaturation with Percutaneous Hepatic Perfusion in Patients with Unresectable Hepatic Metastas
Jul 06, 2016 09:00 am ET
European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting
NEW YORK, July 6, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on treatment of primary and metastatic liver cancers, announces that data from a large single hospital experience conducted at Southampton University Hospital in the United Kingdom were presented in an oral presentation at the 6th European Post-Chicago Melanoma/Skin Cancer Meeting held in Munich, Germany from June 30 – July 1, 2016.
Jun 23, 2016 09:00 am ET
Delcath European Patient Education Website Receives Prestigious Digital Health Award
NEW YORK, June 23, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on treatment of primary and metastatic liver cancers, announces that the Company's new website for European patient education - www.againsttheodds.eu - has been awarded a silver medal in the Biannual Digital Health Awards.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.